Related Experiment Video
Updated: Jan 9, 2026

High-throughput and Comprehensive Drug Surveillance Using Multisegment Injection-Capillary Electrophoresis-Mass Spectrometry
Published on: April 23, 2019
Point-of-Care Testing in PKU: A New ERA of Blood Phenylalanine Monitoring
Alex Pinto1, Adam Gerrard1, Suresh Vijay1
1Birmingham Children's Hospital, NHS Trust, Steelhouse Lane, Birmingham B4 6NH, UK.
Insights
Point-of-care testing (POCT) for monitoring phenylalanine (Phe) in phenylketonuria (PKU) offers faster results than standard dried blood spot (DBS) sampling. Caregivers found the POCT system easy to use and preferred it for home-based PKU management.
Area of Science:
- Biochemistry
- Medical Diagnostics
- Patient Monitoring
Background:
- Dried blood spot (DBS) sampling is the standard for monitoring phenylalanine (Phe) in phenylketonuria (PKU) patients.
- Delays in DBS results can impede timely dietary adjustments for PKU management.
- Patients and caregivers desire point-of-care testing (POCT) for convenient home monitoring.
Purpose of the Study:
- To compare blood Phe measurements obtained via POCT with the standard DBS method.
- To evaluate caregiver usability of a home-based POCT system for PKU monitoring.
Main Methods:
- Twenty participants (18 PKU patients, 2 controls) were enrolled.
- Caregivers performed home-based blood Phe measurements using both a POCT device (Egoo Phe system) and DBS sampling.
- POCT results were compared to DBS analyzed by tandem mass spectrometry (TMS); caregiver usability was assessed via questionnaires.
Main Results:
- A strong correlation was observed between POCT and DBS Phe measurements (R² = 0.8450, p < 0.0001).
- POCT readings were slightly higher than DBS (mean 4.6% difference).
- Caregiver usability improved with practice, and all preferred the POCT system over DBS.
Conclusions:
- The POCT system shows high concordance with DBS for measuring blood Phe levels in PKU patients.
- High caregiver acceptance and improved usability suggest POCT can enhance PKU care.
- POCT facilitates faster, patient-driven monitoring, potentially leading to more timely clinical decisions.
Abstract:
Background: In phenylketonuria (PKU) patients, dried blood spot (DBS) sampling remains the standard method for monitoring phenylalanine (Phe) levels. However, delays in reporting results can hinder timely dietary adjustments. Patients and caregivers have expressed a preference for point-of-care testing (POCT) devices that enable home-based monitoring. Objectives: Our aim was to compare blood Phe measurements in PKU patients and caregiver usability of a POCT system with DBS, which is the standard practice monitoring method. Methods: Twenty participants (eighteen children with PKU and two healthy controls) were recruited. Caregivers of children with PKU were asked to perform blood Phe measurements at home under the supervision of a researcher, using both the POCT device (Egoo Phe system) and DBS sampling. Healthy controls collected the same number of samples using both methods in a hospital setting. The POCT system required 40 µL of blood and used an enzymatic, bioluminescent detection system. DBS samples were analyzed by tandem mass spectrometry (TMS) and required two blood spots (approximately 100 µL of blood). The Egoo Connect App, linked via Bluetooth to the POCT device, displayed results after 29 min. Caregiver usability of the POCT system was assessed using questionnaires at each visit. Results: A total of 100 paired samples were collected. Median values were 274 μmol/L (range: 30-1039) for POCT and 270 μmol/L (range: 20-1190) for DBS. POCT readings were a mean of 4.6% higher than DBS with a noticeable strong correlation observed (y = 1.017x; R2 = 0.8450; p < 0.0001). The usability of the POCT system improved with caregiver practice, and all caregivers expressed a preference for POCT over DBS. Conclusions: The POCT system for blood Phe demonstrated strong concordance with DBS and high caregiver acceptance, highlighting its potential to transform PKU care through faster, patient-driven monitoring and more timely clinical decision-making.
More Related Videos
05:56Implementation of Non-invasive Point of Care Transient Elastography for Evaluation of Liver Disease in Pediatric Populations with Cystic Fibrosis
Published on: August 29, 2025
10:16In Vitro Enzyme Measurement to Test Pharmacological Chaperone Responsiveness in Fabry and Pompe Disease
Published on: December 20, 2017
Related Concept Videos
Inborn Errors of Metabolism
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Therapeutic Drug Monitoring: Drug Analysis Methods
Serum Laboratory Studies, Stool Test, Breath Test